Glaukos Co. (NYSE:GKOS) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lowered its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 9.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,325,784 shares of the medical instruments supplier's stock after selling 131,749 shares during the period. Janus Henderson Group PLC owned approximately 2.40% of Glaukos worth $172,720,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Values First Advisors Inc. acquired a new stake in shares of Glaukos during the third quarter valued at about $25,000. Harvest Fund Management Co. Ltd boosted its stake in shares of Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 860 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock valued at $141,000 after purchasing an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Glaukos during the second quarter valued at about $187,000. Finally, KBC Group NV lifted its stake in shares of Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after acquiring an additional 201 shares during the period. Institutional investors own 99.04% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on GKOS shares. Stifel Nicolaus lifted their target price on Glaukos from $145.00 to $153.00 and gave the stock a "buy" rating in a report on Monday. Morgan Stanley cut Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 target price on the stock. in a research report on Monday. Truist Financial lifted their target price on Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a research report on Monday, October 14th. BTIG Research lifted their target price on Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Finally, StockNews.com raised Glaukos from a "sell" rating to a "hold" rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $136.18.

Glaukos Stock Performance

NYSE:GKOS traded up $2.27 during mid-day trading on Wednesday, hitting $138.27. 634,791 shares of the company traded hands, compared to its average volume of 570,247. The stock's fifty day moving average price is $134.76 and its 200-day moving average price is $125.44. Glaukos Co. has a one year low of $59.58 and a one year high of $146.86. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a market cap of $7.62 billion, a price-to-earnings ratio of -45.78 and a beta of 1.03.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business's quarterly revenue was up 23.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.50) earnings per share. Research analysts anticipate that Glaukos Co. will post -1.91 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now owns 32,336 shares of the company's stock, valued at approximately $4,225,345.12. This trade represents a 8.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at $14,198,425.93. The trade was a 2.18 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.40% of the company's stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.